Revolution Medicines Receives FDA Approval for Rasonque One Month After Filing
Revolution Medicines (RVMD) received full FDA approval for its drug daraxonrasib, branded as Rasonque, just one month after filing. The rapid approval is part of the Commissioner's National Priority Voucher program designed to expedite critical treatments. Rasonque treats metastatic pancreatic cancer and uses a novel mechanism targeting multiple forms of the RAS protein. The FDA approval has driven significant attention and a sharp rise in Revolution Medicines' stock price, which has surged over 178% year-to-date compared to under 13% for the S&P 500. Analysts at RBC Capital Markets project $28 million in sales this quarter with potential peak annual global sales of up to $11.5 billion. The European Medicines Agency has also granted accelerated review status, suggesting international regulatory momentum. CEO Mark Goldsmith emphasized that the approval validates Revolution's strategy targeting a major driver of pancreatic and other cancers.
Tickers: $RVMD
Topics: biotech drug approval pharmaceuticals